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Abstract
Background: Antimicrobial resistance is fast becoming a global concern with rapid increases in
multidrug-resistant Gram negative organisms. The prevalence of extended spectrum beta-
lactamase (ESBL)-producing clinical isolates increases the burden on implementing infectious
disease management in low socio-economic regions. As incidence can vary widely between regions,
this study was done to determine resistance patterns of Gram-negative organisms at Bugando
Medical Center, a tertiary hospital in Mwanza, Tanzania.
Methods: A total of 800 clinical samples (urine, wound swab, pus, blood, aspirate, sputum etc)
were processed over a period of 6 months. Gram-negative bacteria were identified using
conventional in-house biochemical tests and susceptibility to common antibiotics done using disc
diffusion methods. The disc approximation method was used to identify ESBL producers.
Results: A total of 377 Gram-negative bacteria (GNB) recovered from 377 clinical specimens
were analyzed of which 76.9% were Enterobacteriaceae. Among all GNB, 110/377 (29.2%) were
found to be ESBL producers. Species specific ESBLs rate among Klebsiella pneumoniae, Escherichia
coli, Acinetobacter spp, Proteus spp and other enterobacteria were 63.7%, 24.4%, 17.7%, 6.4% and
27.9% respectively. A statistically significant higher number of inpatients 100/283 (35.3%) compared
to 10/94 (10.6%) of outpatients had ESBL-producing organisms (p = 0.000023). Rates of resistances
to gentamicin, tetracycline, sulphamethaxazole/trimethoprim and ciprofloxacin were significantly
higher among ESBLs isolates than non-ESBL isolates (p = 0.000001).
Conclusion: ESBL producing organisms are common at BMC (Bugando Medical Center) and pose
a challenge to antibiotic therapy. Successful implementation of a routine detection of ESBL
production is essential in designing appropriate antibiotic prescribing policies and infection control
intervention programmes.
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Background
Antimicrobial resistance among enteric Gram negative
bacteria is fast becoming a global public health concern
with rapid increase in multidrug resistant organisms [1].
Gram negative bacteria (GNB) are a common cause of uri-
nary tract infections, neonatal sepsis and post surgical
infections in hospitalized patients [1,2]. Resistance of
Enterobacteriaceae to broad spectrum β-lactam antibiot-
ics via ESBL production is an increasing problem world-
wide [2].
The prevalence of ESBL producing clinical isolates is more
than 20% in Asia and South Africa [3]. ESBLs have been
found in 30 to 60% of klebsiellae from intensive care unit
in Brazil, Columbia and Venezuela [4-6]. In North Amer-
ica, National Nosocomial Infection Surveillance revealed
that 6.1% of Klebsiella pneumoniae from 110 intensive care
units were resistant to third generation cephalosporins
[7]. There is considerable geographical variation in the
occurrence of ESBLs in European countries, with marked
hospital to hospital differences within the countries [8].
In Tanzania there is little data on ESBLs epidemiology, in
a study conducted recently at Muhimbili National Hospi-
tal more than 80% of isolates were reported to be resistant
to ampicillin and 25% of Escherichia coli isolates were
resistant to third generation cephalosporins [9,10]. Preva-
lence of ESBL-producing strains in various species of
Enterobacteriaceae differs in different countries and in dif-
ferent hospitals. Usually one of three species (Klebsiella
pneumoniae, Escherichia coli,  Enterobacter spp) predomi-
nates [11].
Antimicrobial agents are the most important tool availa-
ble for managing infectious diseases of bacterial origin.
Some of ESBL are untreatable; an observation that reflects
the formidable challenge that resistance producing strains
can pose in terms of disease control and prevention [2].
The prevention of nosocomial infections and their trans-
mission requires reliable microbiological diagnosis,
rational antibiotic prescribing and effective infection con-
trol. The most important determinants in treating patients
with infections in the ICU is prompt initiation of effective
empirical antimicrobial therapy, taking note of the obser-
vation that inappropriate empirical therapy affects patient
mortality rates [11].
It is therefore essential to address this issue as the corner-
stone to prevent the emergence of multiresistant organ-
isms. This study aimed at addressing the situation at
Bugando Medical Centre in order to provide evidence of
the existence and incidence of ESBL-producing bacteria.
Bugando Medical Centre is a tertiary healthcare institu-
tion with 800 beds and serves a catchment area compris-
ing 13 million people. This study underscores the need for
having in place a routine surveillance of ESBLs and anti-
microbial susceptibility pattern of isolates which are rou-
tinely encountered in clinical practice in this tertiary
health care institution. In addition, it emphasizes the
need for immediate strengthening of hospital-based infec-
tion prevention programmes through effective antimicro-
bial resistance surveillance.
Methods
A total of 800 clinical samples obtained from 800 patients
(male to female ratio of 1.4:1) were processed over a
period of 6 months. These samples included; urine,
wound swabs, pus, blood, aspirate and sputum. Sample
size was estimated using Kish and Lisle formula of cross-
ectional studies [9]. All specimens were delivered and
processed as per standard operating procedures of the lab-
oratory; all incubations were done aerobically for 18–24
hrs [12]. Gram negative bacteria were identified using
colonial morphology on Blood and MacConkey agar
(Oxoid UK) followed by simple biochemical panel (TSI,
Citrate test, SIM, Urease, VP and Methyl red test); negative
and positive controls were included in each test [12]. A
total of 377 clinical specimens with single significant
growth of Gram negative bacteria were included in the
analysis.
Susceptibility testing was done using disc diffusion
method; procedures were performed following guidelines
laid down by the Clinical Laboratory Standard Institute
(CLSI) [13]. Escherichia coli ATCC 25922 was used as qual-
ity control strain. The antibiotic discs representing com-
mon drugs used for treatment of suspected Gram negative
bacterial infection in our hospital were tested, plus other
reserve drugs for Gram negative bacteria commercially
available in our setting. Discs included ampicillin (10 μg),
amoxyillin/clavunate (20/10 μg), ciprofloxacin (5 μg),
tetracycline (30 μg), gentamicin (10 μg), sulfamethoxa-
zole/trimethoprim1.25/23.75 μg) and ceftriaxone. Other
reserve discs included piperacillin/combactam (100/10
μg), ceftazidime (30 μg), cefepime (30 μg), imipenem (10
μg) and meropenem (10 μg) (Oxoid UK).
Test organisms were suspended in normal saline to 0.5
McFarland standard and then inoculated on Muller Hin-
ton agar plates (Oxoid, Wade Road, Basingstoke UK), fol-
lowed by overnight incubation at 37°C for 18–24 hrs.
Interpretation was done using guidelines laid down in the
CLSI manual, which provides break points corresponding
to zone of inhibition diameter [13].
The isolates were screened for ESBL production using
MacConkey agar with 30 μg/ml cefotaxime and confirmed
using disc approximation method. Ceftazidime (30 μg)
and cefotaxime (30 μg) discs were placed equidistant
from the amoxycillin/clavunate (20/10 μg) disc;
enhanced zone of inhibition towards amoxycillin/clavu-BMC Research Notes 2009, 2:49 http://www.biomedcentral.com/1756-0500/2/49
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nate (20/10 μg) disc was considered as positive result for
ESBL production [13-15]. Data were archived using Excel
and SPSS programmes and all ESBL isolates were pre-
served for future molecular analysis.
The study was approved by BMC/WBUCH Ethics review
board of Weill Bugando University College of Health Sci-
ences. An informed consent was obtained before collec-
tion of appropriate specimens and results were used in the
management of patients.
Results
Three hundred and seventy seven non-duplicate Gram
negative bacteria were isolated over a period of six
months. The isolates included those from urine 156
(41.4%), wound swabs 147 (39.0%), blood 43 (11.4%),
pus 22(5.8%), sputum 3(0.8%), bone chips 5 (1.3%) and
aspirates 1(0.3%). Of 377 isolates, 290 (76.9%) were
enterobacteriaceae.
Isolates recovered included, Escherichia coli (33.7%), Kleb-
siella pneumoniae (24.1%), Pseudomonas spp (12.2%), Aci-
netobacter spp (10.3%) and Proteus spp (8.2%). Other
enterobacteria isolated were Enterobacter spp (2.9%), Mor-
ganella morganii (2.9%), Klebsiella oxytoca (2.3%), Citro-
bacter spp (1%), Serratia spp (0.8%), Salmonella spp (0.8%)
and Sternotrophomonas spp (0.5%).
One hundred and ten isolates were confirmed to produce
ESBL using disc approximation method indicating a prev-
alence of 29.2% ESBL production amongst all GNB as
shown in table 1. Species specific ESBLs rate among Kleb-
siella pneumoniae, Escherichia coli, Acinetobacter spp, Proteus
spp and other enterobacteria were 63.7%, 24.4%, 17.7%,
6.4% and 27.9% respectively p = 0.0001 (table 1). Among
Table 1: ESBL producing organisms in different specimens and among inpatients and outpatients
Isolate (n) ESBL N (%) Inpatients ESBL % Outpatients ESBL %
Escherichia coli (n = 127) 31 (24.4%) 26 (83.8%) 4 (16. 1%)
Blood (n = 8) 7 (87.5%) 7 -
Urine (n = 91) 9 (9.9% 6 3
W/S (n = 26) 13 (50%) 12 1
*Others (n = 2) 2 (100%) 1 -
Klebsiella pneumoniae (n = 91) 58 (63.7%) 52(89.6%) 6 (10.4%)
Blood (n = 31) 29 (93.5%) 29 -
Urine (n = 32) 11 (34.4%) 5 6
W/S (n = 26) 18 (66.6%) 18 -
*Others (n = 2) 0 (100%)
Acinetobacter spp (n = 39) 7 (17.9%) 7 (100%) 0 (0%)
Blood (n = 1) 1(100%) 1 -
Urine (n = 4) 2(50%) 2 -
W/S (n = 24) 4(16.6%) 4 -
*Others (n = 10) 0 2
Proteus spp (n = 31) 2 (6.4%) 2 (100%) 0 (0%)
Blood (n = 1) 0 0 -
Urine (n = 6) 0 0 -
W/S (n = 17) 1(68.6%) 1 -
*Others (n = 7) 1(14.3%) 1
Other enterobacteria (n = 43) 12 (27.9%) 12 (100%) 0 (0%)
Blood (n = 1) - - -
Urine (n = 17) 3(17.6%) 3 -
W/S (n = 22) 9(40.9%) 9 -
*Others (n = 3)
Pseudomonas spp (n = 46) NA NA NA
Blood (n = 1)
Urine ( = 4)
W/S (n = 30)
* Others (n = 11) NA NA NA
*Others = Sputum, aspirates and bones chips, n = 377 (inpatients 283, out patients 94), NA = not applicable.BMC Research Notes 2009, 2:49 http://www.biomedcentral.com/1756-0500/2/49
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283 isolates from inpatients, 100 (35.3%) were found to
produce ESBL as compared to 10.6% of isolates from 94
outpatients as shown in table 1 (chi square = 22, p =
0.0001). Most of the isolates recovered from blood sam-
ples 37(86%) were ESBL producers compared to those
from urine and wound swabs (chi square 79.76, p =
0.000001).
About 95.5% of all GNB were resistant to ampicillin. The
rate of resistances to gentamicin, tetracycline, SXT and cip-
rofloxacin was significantly higher in ESBL-producing
organisms than in non-ESBL producers (P = 0.00001;
table 2). About 95% of ESBL isolates were found to be
resistant to cefepime. A total of 32 (78%) of isolates from
ICU (NICU, AICU) produced ESBL and of these, 27(84%)
were Klebsiella pneumoniae.
Discussion
There is presently little information on antibiotic suscep-
tibility patterns for Gram negative bacteria in Tanzania,
especially in Mwanza. This is the first report on the resist-
ance pattern of gram negatives bacteria in this hospital.
Within this institution, treatment is generally given on
empirical basis, often not guided by culture results. A total
of 377 Gram negative bacteria were recovered from clini-
cal samples, majority of these were from urine and wound
swabs. This is due to the large number of these specimens
compared to other types of samples collected for micro-
biological culture. In the present study Escherichia coli was
the most frequently isolated bacterium and was probably
associated with the high proportion of urine specimens
examined [16]. Acinetobacter spp was commonly recovered
from infected wounds and more than 75% were resistant
to third generation cephalosporins; with one isolate being
resistant to all antibiotics tested. Typical ESBLs production
was observed in 17.9% among Acinetobacter spp. In other
studies ESBL production in Acinetobacter spp has been
found to range from 20% in India to 54.6 per cent in
Korea [17]. Epidemics of Acinetobacter spp resistant to
cephalosporin and carbepenems have been reported in
many surgical centers [18].
In this study most of GNB were resistant to ampicillin
with 92.7% of Escherichia coli being resistant to this drug.
This reflects data previously reported from a study done in
Muhimbili whereby more than 80% of Escherichia coli
were resistant to ampicillin [9]; therefore, the use of this
drug is questionable in suspected GNB infection in our
setting. In the present study about 43.5% of isolates were
resistant to third generation cephalosporins. This preva-
lence is high and could possibly be a consequence of inap-
propriate use of these antibiotics at this tertiary hospital
without a guide of culture results. A heavy use of antibiot-
ics has been reported to be a risk factor for acquisition of
ESBL producing organisms [19]. Several studies have
demonstrated the relationship between third generation
cephalosporins use and acquisition of ESBL-producing
organisms [19-21]. Among all GNB 29.8% of them were
found to produce ESBL, an observation which is concord-
Table 2: Rate of resistances to SXT, TE, CIP and G among ESBLs and Non ESBL
Isolates SXT (% R) TE (% R) CIP (% R) G (% R)
Acinetobacter spp (n = 39) 87.2 84.6 43.6 76.9
Non ESBL (n = 32) 65.6 62.5 25 53
ESBL (n = 7) 100 100 43 100
Escherichia coli (n = 127) 65.4 59.1 33.1 29.1
Non ESBL (n = 96) 58.3 48.9 23.9 8.3
ESBL (n = 31) 87.1 93.5 61.3 93.5
Klebsiella pneumoniae (n = 91) 48.3 74.7 45 68.1
Non ESBL (33) 51.5 48.5 6.1 12.1
ESBL (58) 72.4 89.6 20.7 100
Proteus spp (n = 31) 58.4 - 0 16.3
Non ESBL (29) 55.1 - 0 10.3
ESBL (2) 100.0 - 0 100.0
Other enterobacteria (n = 43) 72 44.2 21 34.8
Non ESBL (n = 31) 61.3 38.7 12.9 9.6
ESBL (n = 12) 100.0 58.3 41.6 100.0
Pseudomonas spp (n = 46) 97.8 93.5 19.6 34.8
SXT = Sulphamethaxazole/trimethoprim, TE = tetracycline, CIP = ciprofloxacin, and G = GentamicinBMC Research Notes 2009, 2:49 http://www.biomedcentral.com/1756-0500/2/49
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ant with findings from studies in South Africa and Asia
[3].
Varieties of Gram negatives enteric bacteria were found to
produce ESBLs in our hospital. ESBL production among
Escherichia coli was 24.4%; this is similar to what was
observed at Muhimbili National Hospital Tanzania by
Bloomberg et al [9]. There was significantly higher isola-
tion of ESBL among Klebsiella pneumoniae (63.7%) than
among other enteric Gram negative bacteria p = 0.00001.
A similar finding has been previously described in a study
done elsewhere [5,8,20]. Klebsiella pneumoniae was the
commonest isolate from ICU, Neonatal ICU and prema-
ture unit and significant amount of them were ESBL pro-
ducers. This finding agrees with those described in more
than 75% of previous studies, where the majority of Kleb-
siella pneumoniae isolates were found to produce ESBL [19-
21].
The predilection for ESBL production by Klebsiella pneumo-
niae has never been clearly explained. Almost all non-
ESBL producing Klebsiella pneumoniae isolates have chro-
mosomally mediated SHV-1 β-lactamase [22]. This could
also explain why 100% of our Klebsiella pneumoniae and
Klebsiella oxytoca were resistant to ampicillin. In this study
other enteric bacteria like Proteus spp, Morganella morganii,
Serratia spp, Citrobacter spp and Salmonella spp were found
to produce ESBL at lower rates, similar to results obtained
in other studies else where [1-3].
The prevalence of ESBL is high and poses threat in the
treatment of serious infection due to these isolates. Most
of ESBL-producing isolates in the present study were sig-
nificantly resistant to gentamicin, SXT, tetracycline and
ciprofloxacin p = 0.00001. Under such circumstances, the
only treatment choices are the carbepenems which are
expensive and often not available in most centers in our
country. Many ESBL genes are on large plasmids, which
carry multiple resistance genes [16]; this can explain why
most of our ESBL producing organisms were significantly
resistant to multiple antibiotics. All the ESBL isolates from
this study were sensitive to meropenem and imipenem.
Carbepenems have been considered as drugs of choice to
ESBL isolates; different studies and clinical trials support
the use of these drugs [23,24].
In this study it was found that most of the isolates recov-
ered from blood culture were producing ESBL and this
was associated with an increased mortality of those
patients. This was also demonstrated in the study from 39
patients at Muhimbili National Hospital, Tanzania [9].
Most of blood stream infections in the present study were
from NICU, AICU and Premature unit; these units
accounted for 42% of all ESBL isolates in this study. Inten-
sive care units seem to be the epicenter of ESBL-produc-
tion in the hospital. A similar finding has been
demonstrated previously in which more than 40% of hos-
pital's ESBL-producing organisms were recovered from
intensive care units [25]. The spread of ESBL in these units
can be due to the clonal spread of a single strain or spread
of mobile genetic elements among enterobacteriaceae [1].
In our study the majority of patients with ESBLs blood
stream infections were successfully treated with mero-
penem; early detection and early initiation of the appro-
priate drug was associated with increased survival. Other
investigators have also reported similar trend [26,27].
Approximately three quarters of the isolates were from
inpatients and of these 35.3% were found to produce
ESBL. This was significantly higher than in outpatients p =
0.00001. Some other studies have demonstrated a statisti-
cally significant increase in antibiotic resistance in those
organisms isolated after 72 hours of admission [27,28].
This suggests that nosocomial acquired organisms are
more likely to become ESBL and this is likely to result in
treatment failure with empirical use of cephalosporins.
Conclusion
ESBL isolates are prevalent in our setting and they are mul-
tiply resistant to gentamicin, ciprofloxacin, tetracycline
and sulphamethaxazole/trimethoprim. Routine detection
of ESBL isolates and proper control measures are recom-
mended so that appropriate management can be insti-
tuted.
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